文献速递艾滋病与性传播感染

罗米地辛在HIV-1抑制性抗逆转录病毒治疗患者中的1/2期随机安慰剂对照试验

A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy.
PubMed 文献 · J Infect Dis · 2021-01-01

该1/2期随机安慰剂对照试验在HIV-1 RNA<40拷贝/mL的抗逆转录病毒治疗患者中评估组蛋白去乙酰化酶抑制剂罗米地辛的安全性及诱导HIV-1表达的效果。单剂量队列1-3共43人(36人接受0.5、2、5 mg/m²罗米地辛,7人安慰剂),多剂量队列4共16人(13人接受5 mg/m²罗米地辛,3人安慰剂)。罗米地辛输注安全,但未增加血浆病毒血症或未剪接细胞相关HIV-1 RNA,尽管对CD4+ T细胞有药效学效应。

要点

  • 罗米地辛在抑制性ART的HIV-1感染者中输注安全,仅1例3级中性粒细胞减少可能与治疗相关。
  • 罗米地辛未显著增加血浆病毒血症或未剪接细胞相关HIV-1 RNA。
  • 队列4中罗米地辛降低CD4+ T细胞比例并增加H3K9ac+和磷酸化P-TEFb。

核心结论

  • 罗米地辛输注安全,但未增加血浆病毒血症或未剪接细胞相关HIV-1 RNA,尽管对CD4+ T细胞有药效学效应。

研究设计与样本

  • 1/2期随机安慰剂对照试验, enrollees为HIV-1 RNA<40拷贝/mL的抗逆转录病毒治疗患者。
  • 单剂量队列1-3共43人(36人接受0.5、2、5 mg/m²罗米地辛,7人安慰剂),多剂量队列4共16人(13人接受5 mg/m²罗米地辛,3人安慰剂)。

主要发现

  • 1例3级事件(中性粒细胞减少)可能与治疗相关。
  • 队列1-4中与安慰剂相比未观察到病毒血症显著变化。
  • 队列4中罗米地辛药效学效应:输注2-4后24小时CD4+ T细胞比例降低(中位数-3.5%至-4.5%) vs 安慰剂(中位数0.5%至1%;P ≤ .022)。
  • 队列4中CD4+ T细胞中H3K9ac+和磷酸化P-TEFb较安慰剂增加(P ≤ .02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Romidepsin (RMD) is a histone deacetylase inhibitor reported to reverse HIV-1 latency. We sought to identify doses of RMD that were safe and induced HIV-1 expression. METHODS: Enrollees had HIV-1 RNA <40 copies/mL on antiretroviral therapy. Measurements included RMD levels, plasma viremia by single-copy HIV-1 RNA assay, HIV-1 DNA, cell-associated unspliced HIV-1 RNA (CA-RNA), acetylation of histone H3-lysine-9 (H3K9ac+), and phosphorylation of transcription factor P-TEFb. Wilcoxon tests were used for comparison. RESULTS: In the single-dose cohorts 1-3, 43 participants enrolled (36 participants 0.5, 2, 5 mg/m 2 RMD; 7 placebo) and 16 enrolled in the multidose cohort 4 (13 participants 5 mg/m 2 RMD; 3 placebo). One grade 3 event (neutropenia) was possibly treatment related. No significant changes in viremia were observed in cohorts 1-4 compared to placebo. In cohort 4, pharmacodynamic effects of RMD were reduced proportions of CD4+ T cells 24 hours after infusions 2-4 (median, -3.5% to -4.5%) vs placebo (median, 0.5% to 1%; P ≤ .022), and increased H3K9ac+ and phosphorylated P-TEFb in CD4 + T cells vs placebo (P ≤ .02). CONCLUSIONS: RMD infusions were safe but did not increase plasma viremia or unspliced CA-RNA despite pharmacodynamic effects on CD4 + T cells. CLINICAL TRIALS REGISTRATION: NCT01933594.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. McMahon DK, Zheng L, Cyktor JC, et al. A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy. J Infect Dis. 2021. PMID: 34398236. doi:10.1093/infdis/jiaa777

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。